Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
18 hedge funds and large institutions have $79.5M invested in Vincerx Pharma, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 7 closing their positions.
302% more capital invested
Capital invested by funds: $19.8M → $79.5M (+$59.8M)
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
50% more funds holding
Funds holding: 12 → 18 (+6)
26.91% more ownership
Funds ownership: 19.42% → 46.33% (+27%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$7.88M |
| 2 |
Holocene Advisors
New York
|
+$5.82M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$4.73M |
| 4 |
PA
Perceptive Advisors
New York
|
+$4.73M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.36M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$2.27M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$1.55M |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$1.24M |
| 5 |
GCL
Glazer Capital LLC
New York
|
-$859K |
VINC Hedge Fund Activity: Q4 2020 in Review
18 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q4 2020, worth a combined $79.5M — up 302% from $19.8M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VINC positions and 7 closed out — a net gain of 6 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $7.88M. The largest seller was EcoR1 Capital, cutting an estimated $2.36M.
- 18 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q4 2020, up from 12 in Q3 2020.
- Funds reported $79.5M of Vincerx Pharma, Inc. Common Stock stock for Q4 2020, up 302% quarter-over-quarter.
- 13 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q4 2020 and 7 closed out, a net change of +6 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q4 2020 was RTW Investments, an estimated $7.88M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q4 2020 was EcoR1 Capital, an estimated $2.36M sold.
Based on aggregated 13F filings for Q4 2020.